AstraZeneca PLC [NASDAQ: AZN] gained 0.62% on the last trading session, reaching $59.63 price per share at the time. The company report on July 9, 2021 that EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration.
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announces that it has signed a material transfer agreement (“MTA”) with MedImmune Limited, an affiliate of AstraZeneca AB (LSE/STO/Nasdaq: AZN) (“AZ”), to facilitate the trialing of EnWave’s Radiant Energy Vacuum (“REV”) technology for the dehydration of liquid monoclonal antibody formulations. AZ will send proprietary materials to EnWave’s testing facility in Vancouver, Canada to conduct initial proof-of-concept trials. If successful, the two companies intend to negotiate a more robust agreement to allow for further research and development activities.
About AstraZeneca ABAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
AstraZeneca PLC represents 2.62 billion in outstanding shares, while the company has a total market value of $155.60 billion with the latest information. AZN stock price has been found in the range of $59.07 to $59.91.
If compared to the average trading volume of 7.82M shares, AZN reached a trading volume of 6137360 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $63.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Argus have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Hold, with their previous recommendation back on April 12, 2021. The new note on the price target was released on March 16, 2021, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 0.80, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.64. The Price to Book ratio for the last quarter was 10.84, with the Price to Cash per share for the same quarter was set at 2.98. Price to Free Cash Flow for AZN in the course of the last twelve months was 79.55 with Quick ratio for the last quarter at 0.70.
Trading performance analysis for AZN stock
AstraZeneca PLC [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.13. With this latest performance, AZN shares gained by 3.52% in over the last four-week period, additionally plugging by 18.81% over the last 6 months – not to mention a rise of 10.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 59.96, with the RSI for the last a single of trading hit 56.10, and the three-weeks RSI is set at 61.80 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 57.01, while it was recorded at 59.87 for the last single week of trading, and 53.01 for the last 200 days.
AstraZeneca PLC [AZN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +16.98 and a Gross Margin at +74.01. AstraZeneca PLC’s Net Margin is presently recorded at +11.58.
Return on Total Capital for AZN is now 14.29, given the latest momentum, and Return on Invested Capital for the company is 10.66. Return on Equity for this stock inclined to 23.36, with Return on Assets sitting at 5.24. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 130.46. Additionally, AZN Total Debt to Total Capital is recorded at 56.61, with Total Debt to Total Assets ending up at 30.54. Long-Term Debt to Equity for the company is recorded at 115.18, with the Long-Term Debt to Total Capital now at 49.98.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $32,750 per employee. Receivables Turnover for the company is 5.35 with a Total Asset Turnover recorded at a value of 0.45.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.90.
AstraZeneca PLC [AZN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 18.50%.
An analysis of insider ownership at AstraZeneca PLC [AZN]
There are presently around $24,581 million, or 16.80% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 58,047,130, which is approximately 212.137% of the company’s market cap and around 0.50% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 49,913,226 shares of the stock with an approximate value of $2.98 billion in AZN stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $2.94 billion in AZN stock with ownership of nearly 1.386% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 337 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 75,363,326 shares. Additionally, 366 investors decreased positions by around 58,092,705 shares, while 138 investors held positions by with 278,761,098 shares. The mentioned changes placed institutional holdings at 412,217,129 shares, according to the latest SEC report filing. AZN stock had 78 new institutional investments in for a total of 4,583,208 shares, while 98 institutional investors sold positions of 7,796,405 shares during the same period.